Fentagesic 25 mikrograma/h transdermalni naljepak
Name | Fentagesic 25 mikrograma/h transdermalni naljepak |
---|---|
Marketing Authorisation Number | HR-H-533253911 |
Active Substance | fentanil |
Composition | jedan transdermalni naljepak sadrži 4,125 mg fentanila |
Pharmaceutical Form | transdermalni naljepak |
Manufacturer | Pliva Hrvatska d.o.o., Zagreb, Hrvatska
Merckle GmbH, Blaubeuren, Baden-Wuerttemberg, Njemačka Merckle GmbH, Ulm, Baden – Wuerttemberg, Njemačka Luye Pharma AG, Miesbach, Njemačka |
Marketing Authorisation Holder | Pliva Hrvatska d.o.o., Prilaz baruna Filipovića 25, Zagreb, Hrvatska |
Marketing Authorisation Date | 27.04.2020 |
MA Period of Validity | unlimited |
MA Revocation Date | 23.04.2024* |
Classification Number | UP/I-530-09/18-02/54 |
Registration Number | 381-12-01/38-20-03 |
Prescription | na recept |
Type of prescription | poseban recept |
Distribution | u ljekarni |
Advertising to general public | zabranjeno |
ATC Code | N02AB03 |
Medicinal product marketed in the Croatia | Trajni prekid opskrbe |
SmPC | download |
PL | download |
*Note
Marketing authorisation has been revoked by request of the marketing authorisation holder. In accordance with Article 113 of Medicinal Products Act (Official Gazette No. 76/13), only a medicinal product in respect of which a marketing authorisation has been granted by the Agency for Medicinal Products and Medical Devices or the European Commision, and a medicinal product in respect of which an authorisation for parallel import or parallel distribution has been granted may be placed on the market of the Republic of Croatia. By way of derogation from this provision, a batch of medicinal product may be on the market for no longer than 18 months following the expiry of revocation of the marketing authorisation, unless its shelf life expires first.